Phase III Will Be Real Test For vTv's Resurrected Alzheimer's Drug
Phase IIb data for vTv Therapeutics' lead product azeliragon have demonstrated an effect on cognitive deterioration in mild Alzheimer’s disease patients – but is this evidence enough to get the small biotech back on track after it lost Pfizer Inc. as a partner for the drug in 2012?
You may also be interested in...
Continuing Dismay In Alzheimer's: vTv's RAGE Antagonist Fails In Phase III Study
A further mechanism of action has proven ineffective in top-line data from a late-stage study in Alzheimer's disease, adding to the long list of tried and failed approaches to the seemingly intractable condition.
Alzheimer’s Update: Amyloid Hypothesis Lives On At Biogen, Lilly, Merck, Pfizer, Roche
Biogen rose and fell based on the company’s latest aducanumab results, but the Clinical Trials on Alzheimer’s Disease meeting Dec. 8-10 showed that regardless of Lilly’s Phase III solanezumab failure, companies continue to invest in amyloid and other hypotheses, including BACE, gamma secretase and other programs.
Glucokinase Activation Gets Boost With vTv Therapeutics' Phase II Data
vTv Therapeutics has released promising top-line data for its novel diabetes therapy TTP399, the leading product in a tricky new class of glucokinase activators, but the magnitude of the effect is still unclear and progress to Phase III awaits a partnering program.